Takeda posts results for TAK-881 vs HYQVIA pharmacokinetic study in PIDD patients
Takeda's Phase 2/3 crossover trial comparing TAK-881 to HYQVIA in primary immunodeficiency diseases reached completed status with results posted September 30, 2026.
Takeda had one notable immunology update during the week, a completed pharmacokinetics study with results posted.
- Takeda's trial of TAK-881, a subcutaneous immunoglobulin formulated with recombinant human hyaluronidase, compared it against HYQVIA in people with primary immunodeficiency diseases. The Phase 2/3 study enrolled 65 participants.1 The study's overall status is completed, with results first posted on 2026-09-30.1 The primary outcome measured the area under the curve over one dosing interval at steady-state for total IgG levels, comparing TAK-881 and HYQVIA in participants 16 years and older.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.